Intralase in the East Bay and Oakland
September 5th, 2006
Turner Eye Institute uses the most advanced FS Laser System for the Intralase laser. Results have been exceptional. At the current time, Dr. Stephen Turner tends to select the intralase laser for hyperopic patients and patients with a significant amount of astigmatism. Dr. Turner chooses these cases as they have a slightly higher chance of complications when using a standard microkeratome. For myopic patients, Dr. Turner still tends to select the Thin Flap LASIK, also depending on topography and the shape of surrounding ocular tissue.
Turner Eye Institute uses intralase at the east bay facility south of Oakland in San Leandro. Patients from San Jose, San Francisco, and Concord and Walnut Creek still have access to Intralase though this East Bay facility.
Here is a recent newspaper article regarding Intralase.
IntraLase Receives Approval in Taiwan for Sales of Its FS Laser System; Company Plans Immediate Commercialization to Further Expand Global Presence
IRVINE, Calif.–(BUSINESS WIRE)–Aug. 29, 2006–IntraLase Corp. (NASDAQ:ILSE), manufacturer of the ultra-fast laser that is revolutionizing refractive and corneal surgery, today announced that Taiwan has granted approval for the sale of the company’s femtosecond laser in that nation.
The company plans to immediately commercialize the IntraLase(R) FS laser in Taiwan, further expanding its global presence. As of June 30, 2006, 471 IntraLase lasers were installed around the world and over 850,000 IntraLase LASIK procedures had been performed in ophthalmic practices worldwide.
Taiwan Hwa-In, IntraLase’s distributor in Hong Kong and Mainland China, will begin offering the company’s products in Taiwan immediately. Mr. Jay Hsu, Chief Executive Officer of Taiwan Hwa-In, stated, “The added safety of the IntraLase Method(TM) in LASIK will provide excellent momentum to drive patient demand in Taiwan, which has a very large number of patients seeking safer and more reliable treatments.” Mr. Hsu continued, “Taiwan Hwa-In is a leader in the Taiwanese refractive market, with over 20 years experience, and this approval allows us to help doctors in Taiwan provide bladeless LASIK surgery to their patients.”
“The Taiwanese market represents an exciting opportunity and further demonstrates the global potential of IntraLase technology,” said Robert J. Palmisano, President and Chief Executive Officer of IntraLase Corp. “We look forward to entering this market and helping Taiwanese practitioners offer clinically-proven safety and improved visual outcomes to their patients.”
About IntraLase Corp.
IntraLase designs, develops, and manufactures an ultra-fast laser that is revolutionizing refractive and corneal surgery by creating safe and more precise corneal incisions. Delivering on the promise of ophthalmic laser technology, the IntraLase FS laser, related software, and disposable devices replace the hand-held microkeratome blade used during LASIK surgery. The unsurpassed accuracy of IntraLase’s computer-controlled femtosecond laser has been shown to improve safety profiles and visual outcomes when used during LASIK. Additionally, the IntraLase FS laser creates precision-designed intracorneal incisions that when combined can be used during lamellar and penetrating keratoplasty, and intrastromal ring implantation. IntraLase is presently in the process of commercializing applications of its technology in the treatment of corneal diseases that require corneal transplant surgery. The company’s proprietary laser and disposable patient interfaces are presently marketed throughout the United States and 31 other countries. IntraLase is headquartered and manufactures its products in Irvine, California. For additional information, visit the company’s web site: www.intralase.com.
Forward Looking Statements
Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “project,” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: the degree of continued acceptance of LASIK surgery; potential complications revealed by long-term follow up; the extent of adoption of our product offering by LASIK surgeons; general economic conditions; changes in federal tax laws governing the ability of potential LASIK patients to use pre-tax dollars to pay for LASIK surgery; the scope of government regulation applicable to our products; patients’ willingness to pay for LASIK surgery; our ability to compete against our competitors; the effectiveness of our measures to ensure full payment of procedure fees; the occurrence and outcome of product liability suits against us; our ability to adequately protect our intellectual property; whether we become subject to claims of infringement or misappropriation of the intellectual property rights of others; the continued availability of supplies from single-source suppliers and manufacturers of our key laser components; the ability of our managers, operations, and facilities to manage our growth; the success of our expansion into markets outside the United States; whether we lose any of our key executives or fail to attract qualified personnel; or if our new products or applications fail to become commercially viable.
